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Fabrication oF Voriconazole Solid liPid nanoParticleS For eFFectiVe 
ocular deliVery
Kumar R., Sinha V.R.
UIPS, Panjab University, Chandigarh, India
Objectives: Preparation of Voriconazole (VCZ) solid lipid nanoparticles (SLNs) for 
effective ocular delivery for the treatment of fungal keratitis. MethOds: SLNs were 
prepared by solvent emulsification technique using Compritol (lipid), Pluronic F-68 
(surfactant) and sodium taurocholate (co-surfactant). Characterization of SLNs was 
performed by size measurement, in-vitro release, ex-vivo corneal permeation stud-
ies and in-vitro antifungal activity. Results: Particle sizes were found in the range 
of 150-300 depending upon lipid/Smix ratio with good zeta potential. Entrapment 
efficiency of SLNs was found between 40-60% with sustained in vitro drug release 
(> 70% in 12h). The ex-vivo corneal permeation studies exhibited good ocular per-
meation of VCZ from SLNs. Ex-vivo study also supports good ocular permeation of 
VCZ from SLNs when compared with drug suspension. Further, in-vitro antifungal 
activity exhibited the potential of VCZ SLNs. cOnclusiOns: The sustained release 
property with good corneal permeation of VCZ from SLNs encourages its applica-
tion for in-vivo studies and hence could be proposed as an effective carrier for 
ophthalmic administration.
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the analySiS oF dental care in ukraine at the regional leVel
Zaliskyy O., Shcherba P., Zalis’ka O.
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
Objectives: The structure of the overall incidence diseases the mouth and teeth 
morbidity occupy the third place in Ukraine. Thus 99% of the patients served in 
outpatient clinics institutions. The structure of diseases requiring hospitalization 
(approximately 1% of patients), the top spot is occupied odontogenic inflammatory 
diseases and injuries of the maxillofacial face. MethOds: In Ukraine, the avail-
ability of dentists is 4.0 per 10 000 population and 4.5 per 10 000 children. We have 
analyzed the statistical data of the Lviv Regional Department of Health. We found 
that 98% of the population have dental problems. Prevalence of dental caries, tempo-
rary occlusion in 6-years children reached 87.9%, a 12-year-olds - 72.3%. Prevalence 
of chronic catarrhal gingivitis among adolescents aged 12-15 years ranged 70-98% 
and teeth abnormalities in children 7-18 years more than 80%. In Ukraine every-
one requires a prosthetics after 50 years. Results: Main social burden have the 
dental institutions of the state and municipal property. By 2013 there were about 
1.5 million causes to the dental care. We determined that in Lviv region on the 
basis of licenses to practice medicine in dentistry are 248 dentists, who working 
in cities and towns, and only about 10% - in rural areas. From 196th private den-
tal surgeries 89 are situated in the regional center. Danylo Halytsky Lviv National 
Medical University opened and acting university Dental Center from 2012, where 
dentists had treated about 400 000 people, including more than 172 000 children 
each year. Such preventive examinations make it possible to carry out monitoring 
as indicators of dental public health field, to identify the most important risk fac-
tors for dental diseases. cOnclusiOns: The management and pharmacoeconomic 
studies of dental care, identifying optimal funding for state and municipal health 
care institutions for cost-effectiveness use of state funds.
PSS57
dental care uSe and aSSociated FactorS among PeoPle With 
rheumatoid arthritiS: a nationWide, PoPulation-baSed, ProPenSity 
Score-matched FolloW-uP Study
Chen Y.T.
Yang-Ming University, Taiwan, Taiwan
Objectives: Patients with RA suffer from a higher risk of periodontal attachment 
loss and increased oral inflammation. There were few studies to access the utiliza-
tion of dental care among RA in the Taiwan. The purpose is identify realize analyze 
and discuss the dental use of diabetic patients, and the association between the risk 
of rheumatoid arthritis (RA) and a history of periodontitis. MethOds: retrospective 
cohort studybased on the nationwide, population-based, NHIB used administra-
tive data, case group consisted of 5,506 (age ≥ 18 years) patients with rheumatoid 
arthritis (RA group) as the study group and 22,024 patients without RA attending 
the Outpatient wing of Department of General Medicine formed the control group 
(NRA group). Matched for Age, gender and RUB, Both groups were matched on 1:4.  
Results: More advanced forms of periodontitis were found in RA patients com-
pared with controls. The results showed that RA patients (66.9% of RA) had 5-years 
utilization rate of dental care than non-RA patients (13.9% of non-RA). However, 
people have RA or not, the characteristics of dental use were similar. Only has the 
gender aspects to differ from, when the male suffered from RA, the utilization of 
dental care were not different with the female. cOnclusiOns: we propose that the 
consulting rheumatologists inform the patients that they have a higher risk of peri-
odontal. this study demonstrates an association between periodontitis and incident 
RA. And the study is limited to lack of BMI, smoking, alcohol status.
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macular oedema due to retinal Vein occluSion methodS For the 
identiFication oF treatment guidelineS and areaS oF unmet clinical 
needS by meanS oF SyStematic reVieW
Patel A.S.
Abacus International, Bicester, UK
Objectives: Retinal vein occlusion (RVO) causes macular oedema (MO), which 
can lead to vision loss. The present study sought to identify treatment guidelines 
internationally by conducting a systematic review and extensive hand searches. 
The aims were to i) develop a systematic methodology for the identification of 
such guidelines ii) review the guidelines and treatment pathways identified in 
order to propose optimal positioning for an hypothetical intervention for the treat-
ment of MO in RVO, and iii) to identify areas of unmet clinical needs. MethOds: 
Objectives: To assess the cost-effectiveness of nutritional support (high protein 
supplementary diet) versus standard care (regular hospital diet) in preventing pres-
sure ulcers in hospitalised patients at high risk of pressure ulcers and malnutri-
tion. Further, to evaluate the need and value of additional research using value of 
information analysis. MethOds: Analyses were undertaken from the perspective 
of the State health department in Queensland, Australia, using a Markov decision 
model. Evidence for the relative risk (RR) was estimated from a meta-analysis of 
randomised controlled trials; other parameters were systematically identified from 
the literature to populate the model. The incremental net monetary benefit (INB) 
was calculated and a probabilistic sensitivity analysis using Monte Carlo simulation 
was conducted. The expected value of perfect information (EVPI), expected value 
of perfect parameter information (EVPPI), expected value of sample information 
(EVSI), expected total cost of additional research, expected net benefit of sampling 
(ENBS), and the return on investment (ROI) were calculated for an estimated popula-
tion of 125,000 over ten years. Results: At a willingness-to-pay of AU$ 50,000 per 
quality-adjusted life year, the INB was AU$ 530, with a probability of 84% for nutri-
tional support to be the preferred intervention. The population EVPI was AU$ 4.75 
million, the highest EVPPI was for RR at AU$ 2.25 million. For a future randomised 
study investigating the RR of the two interventions, the ENBS would be maximised 
at AU$ 380,000 with 1,200 patients in each arm; from an EVSI of AU$1.6 million and 
total study cost of AU$ 1.2 million. The expected ROI would be 32%. cOnclusiOns: 
Nutritional support is cost-effective in preventing pressure ulcers in high risk hos-
pitalised patients; however, there is uncertainty surrounding the decision and the 
value of this uncertainty is high. A future clinical trial to resolve this uncertainty 
is worthwhile.
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the imPact oF the german drg-SyStem on Policy deciSion making in 
ent
Fichtenbauer M., Kosaner M., Urban M.
Vibrant Med-El Hearing Technology Gmbh, Innsbruck, Austria
Objectives: The German diagnosis-related groups (G-DRG) have been introduced 
as a reimbursement system for in-patient care. The aim of this study was to report 
on clinic-based data available from the G-DRG browser regarding the impact of 
middle ear implantation as a basis for future health care decision making in 
ear, nose and throat medicine (ENT). MethOds: Using a clinical algorithm, the 
unevaluated D23Z database from 2012 was analyzed to determine epidemiologi-
cal characteristics of patients with different types of hearing losses and receiving 
middle ear implants (MEI). All ICD-10 Codes used for the diagnosis of conduc-
tive (CHL), mixed (MHL) or sensorineural hearing loss (SNHL) were extracted. The 
number of MEI cases reported in the D23Z was analyzed regarding Patient Clinical 
Complexity Level (PCCL), age, sex and duration of stay. The incidence of MEI 
candidates to the total number of ICD-10 codes and per indication were calcu-
lated. Results: According to the D23Z, approximately 30`000 individuals admitted 
to ENT clinics were diagnosed with a hearing loss. About 38% suffered from CHL, 
8% suffered from MHL and 48% suffered from SNHL. The proportion of patients 
who received a MEI per indication were respectively 0.8% for SNHL, 8% for MHL 
and 1% for CHL. Overall, about 466 (1%) patients received a MEI. 49.8% of them 
were men and 50.2% were women. Children aged as young as 1-2 years could 
also receive treatment. All patients had normal-term stay in hospitals with no 
comorbidities or complications (PCCL < 4 in 99.2% of cases) The incidence of MEI 
to the ENT patient base and the German population were respectively 15.5/1,000 
and 0.6/100,000. cOnclusiOns: The overall number of middle ear implantations 
compared to standard treatments is quite low. Analyzing data on MEI available 
from highly-developed DRG systems can be used by other countries for policy 
decision making in ENT.
PSS54
underStanding trendS in oPhthalmologiSt Patient Selection and 
care baSed on PatternS oF billing
Culp J.L.1, Connelly N.1, Kristopik J.1, Doyle J.J.2
1Quintiles Consulting, Durham, NC, USA, 2Quintiles, Hawthorne, NY, USA
The recent U. S. release of Medicare Part B billing data provides unprecedented 
insight into a health care system that reimbursed $77 billion in 2012. Of the 100 
physicians receiving the greatest payments, nearly half were ophthalmologists.  
Objectives: Examine ophthalmologist trends in patient selection and care, 
and implications on system value delivery, based on Medicare and other 
data. MethOds: We examined aggregate and line-item data, comparing the 
100 highest billing ophthalmologists to each other, and to the remaining 16,971, 
identifying patterns in services billed, beneficiaries served, service location, and 
dollars billed, allowed and paid. We also compared volume and cost of a key office-
based code (J2778: Ranibizumab injection) to a key facility-based code (67042: 
vitrectomy for macular hole), and incorporated epidemiology data to understand 
provider incentives and drivers of care. Results: Ophthalmologists represented 
2% of all practitioners billing Part B, but received 7% of reimbursement; the Top 
100 billing ophthalmologists accounted for 0.6% of ophthalmologists billing, but 
received 8.8% of payments; disparities between Top 100 billers and non-Top 100 
include: variety of patients treated, percent of charges reimbursed, and practice 
location; high volume J2778 performers were much more likely to be Top 100 bill-
ers than were high performers of 67042; and based on prevalence among those 
65 and older, a significantly greater percentage of beneficiaries with wet AMD 
received treatment than did beneficiaries with macular hole. cOnclusiOns: 
A large portion of payments were received by relatively few ophthalmologists, 
whose practices demonstrate disparities in variety and volume of procedures 
over non-top billers; incentives—some financial—may be factors that contribute 
to greater treatment of wet AMD than of macular hole; and a focus on conducting 
high-reimbursement services may drive disproportionate system costs. Greater 
transparency may drive changes in practitioner behavior, and reduce unnecessary 
health care system costs.
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cally significant (p> .05), a trend toward more days hospitalized from disease-asso-
ciated complications was observed for patients managed with WW (Mean= 9.21, 
respectively) and non-systemic treatment (Mean= 8.27) than patients treated 
with chemotherapy (Mean= 7.25) or TKIs (Mean= 8.22). cOnclusiOns: Among 
patients diagnosed with RRDTC, watch and wait and non-systemic treatment 
options remain common. A large direct cost burden may be observed given the 
frequent and long hospital stays.
Pcn2
aPProVing drugS baSed on early Stage data - hoW PhaSe ii trial data 
correlateS With PhaSe iii outcomeS. caSe Study: nSclc
Macaulay R., Tan H.
HERON Commercialization, London, UK
Objectives: There is increasing pressure on regulators from patients, physicians 
and industry for earlier access to pharmaceuticals for serious diseases. In reaction, 
in March 2014 the European Medicines Agency (EMA) announced it was piloting 
adaptive licensing, and the Medicines and Health care products Regulatory Agency 
(MHRA) unveiled their Early Access to Medicines Scheme. Nevertheless, there are 
questions over how, and if, Phase II trial benefits can be predictive of clinical advan-
tages in Phase III studies, which this research aims to address. MethOds: Phase 
III data of any Non-Small Cell Lung Cancer (NSCLC) oncologic appraised by the 
EMA, or that had failed Phase III clinical trials, since 2002 was extracted along with 
its corresponding Phase II data. Statistical tests were conducted using Pearson’s 
coefficient correlation. Results: 12 oncologics were identified with both Phase 
II and III readouts, 6 of which met their Phase III trial primary endpoint. Overall 
Response Rates (ORRs) reported in Phase II trials varied from 0%-61% (mean 24%). 
4/4 (100%) drugs with Phase II ORRs > 30% met their primary endpoint vs. only 
2/8 (25%) with ORRs ≤ 30%. Phase II ORRs were strongly correlated with Phase III 
Progression-Free Survival (PFS) (r2= 0.864, p< 0.0005) and Overall Survival (OS) out-
comes (r2= 0.858, p< 0.001). Nevertheless, 5/6 drugs that failed their Phase III primary 
endpoints had comparative Phase II data indicating benefits versus these same 
comparators, most notably onartuzumab, whose Phase III trial was terminated early 
due to lack of efficacy, despite demonstrating significant OS benefits of 8.8 months 
in Phase II. cOnclusiOns: In NSCLC, Phase II ORRs can be strongly predictive of 
the magnitude of PFS and OS readouts in Phase III trials. However, comparative 
advantages in Phase II trials seem to be poorly predictive of OS benefits in Phase 
III studies, raising questions over the appropriateness of approving drugs on early 
stage comparative data.
Pcn4
cerVical human PaPilloma ViruS (hPV) dna Primary Screening teSt 
reSultS oF the exPerience oF a regional laboratory in central italy
Passamonti B.U.1, Bulletti S.1, Gustinucci D.1, Martinelli N.1, D’Amico M.R.1, Spita N.1, 
Malaspina M.1, Carlani A.1, DI Dato E.1, Galeazzi P.1, Tintori B.1, D’angelo V.1, Calvi C.2
1Centro Unico di Screening Regione Umbria, PERUGIA, Italy, 2ROCHE DIAGNOSTICS, MONZA, 
Italy
Objectives: To investigate feasibility and effectiveness of a cervical screening 
program with DNA tests as preliminary assay versus usual cytology protocols in 
Umbria Region. MethOds: A large cohort of 35-64 aged women afferent to the 
unique regional laboratory was considered. The usual algorithm with cervical cytol-
ogy as primary test was followed in January 2008–June 2010, whereas in August 
2010–October 2011 high-risk human papillomavirus (HR-HPV) DNA test was used 
as primary screening. The cohorts were compared in terms of acceptance rate of 
invitation, cytological results, molecular results including HPV genotype, detection 
rate of histological lesions. Results: A total of 31,228 women were invited: 21,249 
were suggested to undergo classical cervical cytology screening, 9,979 HR-HPV DNA 
test as primary screening. A similar rate of adhesion (56.6% vs. 56.5%) was observed. 
Age-related differences were evidenced, with younger women (35-49) more prone to 
accept the invitation to HR-HPV DNA testing rather than usual cytology screening 
(61.6% vs. 55.5%; p< 0.0001); analogously, uninvited younger women spontaneously 
requesting cervical screening were more prone to specifically request molecular 
than classical cytological testing (24.8% vs. 10.8%; p< 0.0001). Among the 6,272 
HR-HPV DNA testing women, 396 (6.4%) were positive, and, among them, 141 (36%) 
featured an altered cytology. All patients with altered cytology were suggested to 
undergo colposcopy and 106 out of 141 (75.1%) answered to the invitation. Among 
them, 89 (84%) featured abnormal histology with 48 (45.3%) CIN1 and 41 (38.7%) 
CIN2. If comparing the CIN2 detection rate within the two studied periods, it was 
almost doubled using the HR-HPV DNA than pap test as primary assay (0.64% vs. 
0.37%; p= 0.005). Finally, the implementation of the DNA test screening program did 
not increase total costs. cOnclusiOns: Although with some limits, the introduc-
tion of HR-HPV DNA primary testing resulted feasible and effective, significantly 
increasing detection of severe lesions.
Pcn5
comParatiVe eFFectiVeneSS oF treatmentS For relaPSed or 
reFractory mantle cell lymPhoma (r/r mcl), uSing matching 
adjuSted indirect comPariSon
Tongbram V.1, Sengupta N.2, Gaudig M.3, Sidhu M.1, Exuzides A.4, Colby C.4, Sanden S.V.5, 
McGovern A.1
1ICON Plc, Morristown, NJ, USA, 2Janssen Pharmaceuticals, Inc, Raritan, NJ, USA, 3Janssen 
Pharmaceuticals, Inc, Neuss, Germany, 4ICON Plc, San Francisco, CA, USA, 5Janssen 
Pharmaceuticals, Inc., Beerse, Belgium
Objectives: Prognosis for relapsed or refractory (R/R) MCL patients with existing 
treatments is poor; most patients progress within ~4 months. Ibrutinib, an oral once 
daily Bruton’s tyrosine kinase inhibitor showed durable single agent activity with 
good response rate in 111 R/R MCL patients and a median progression free survival 
(PFS) of 13.9 months. Ibrutinib received breakthrough designation and United States 
Food and Drugs Administration approval for use in MCL patients who received at 
least one prior therapy (R/R MCL). This indirect analysis aims to compare the efficacy 
Systematic searches in the electronic databases MEDLINE, EMBASE and The 
Cochrane library were conducted and 53 online databases (including HTA agency 
websites, international ministries of health, and clinical trials. gov) were hand 
searched for clinical guidelines in the treatment of MO caused by RVO. Results: 
Fifteen documents on treatment pathways or guidance used internationally were 
identified from the hand searches. No papers or abstracts were found from the 
electronic database searches. There were considerable between-jurisdiction dif-
ferences in the guidance for the management of MO caused by RVO. These differ-
ences were consolidated to produce two amalgamated treatment pathways. In 
total, eight treatment positions for interventions in the treatment of RVO subtypes 
were identified. For one of the identified positions – treatment of ischaemic branch 
RVO – no licensed treatment currently exists. cOnclusiOns: The described sys-
tematic methodology for the construction of treatment pathways may be used 
by manufacturers in early drug development decisions to identify unmet clini-
cal needs, understand which treatment positioning may provide the most value, 
and identify future treatment comparators in the same indication. Guidelines 
to inform such commercial strategies may not be identifiable from electronic 
database searches alone with extensive hand searches being a necessity. Between 
jurisdiction guideline nuances also need to be taken into account when consider-
ing the target market for an intervention in development.
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oPhthalmology: theraPy trendS in euroPe baSed on clinical trial 
regiStry data
Gupta A., Mukherjee B., Mahal S.S., Mathews A.
Novartis Healthcare Pvt Ltd, Hyderabad, India
Objectives: Ophthalmology pharmaceutical market is growing worldwide due 
to rising aging population, new delivery technologies and changing lifestyle. 
However, challenges like patent expiry of major brands and lack of awareness 
still persists. Therefore, it is important to be aware of the upcoming treatment 
options, changing patients’ needs and requirement of cost effective therapies. 
This analysis provides an overview of the recent trends and future scenario in 
Ophthalmology market. MethOds: Pharmaceutical companies sponsored clinical 
trials initiated from January 2011 to April 2014 in Glaucoma, Age-related Macular 
Degeneration (AMD), Diabetic Retinopathy (DR) / Diabetic Macular Edema (DME), 
Dry eye syndrome (DES) and Retinal vein occlusion (RVO) have been considered. 
Only Phase I - III trials listed on public registries have been considered. Results: 
The data showed that > 30% of the trials are being conducted on Glaucoma in 
USA, Europe, Asia and Australia. This is followed by AMD (24%), DR/DME (21%), 
DES (17%) and RVO (7%). Also, > 50% ophthalmological trials are being conducted 
in USA; followed by Europe (~25%) and Asia (~20%). In Europe, 71 trials have been 
conducted on 48 molecules, of which 69% are chemical entities, 19% are biologicals 
and > 10% are entities like RNAi (oligonucleotide, aptamers), DARPin. Eye drops 
(46%) and intravitreal injections (37%) are the key topical and parenteral formula-
tions, respectively. 10% of the trials have been conducted on oral formulations. In 
Europe, EU5 countries comprise of 43% of the trials and Germany has maximum 37 
trials. Novartis has conducted trials in maximum 30 countries, followed by Santen 
(19), Pfizer (15) and Allergan (13) in Europe. cOnclusiOns: Based on the analysis, 
currently, Glaucoma, AMD and DR/DME are the major focus of the companies in 
ophthalmology. Though, biologicals and RNAi are being tested routinely, chemical 
entities are foremost modalities. Similarly, eye drops remain as preferred method 
of delivery with respect to other newer delivery techniques.
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treatment PatternS and health outcomeS among PatientS With 
radioiodine-reFractory diFFerentiated thyroid cancer in the 
united StateS and WeStern euroPe
Gianoukakis A.G.1, Flores N.M.2, Pelletier C.L.3, DiBonaventura M.2, Forsythe A.3, Wolfe G.2, 
Rege J.3, Taylor M.H.4
1University of California, Los Angeles, Torrance, CA, USA, 2Kantar Health, New York, NY, USA, 
3Eisai Inc, Woodcliff Lake, NJ, USA, 4Oregon Health & Science University, Division of Hematology 
& Medical Oncology, Portland, OR, USA
Objectives: Most patients with differentiated thyroid cancer (DTC) have an 
excellent prognosis after receiving standard treatment, consisting of surgery and 
often adjuvant radioactive iodine (RAI). However, a subgroup of patients prove to 
have progressive DTC which is refractory to RAI (RRDTC). Treatment options for 
RRDTC are limited. This study investigated the treatment patterns and health care 
resource utilization of patients with RRDTC. MethOds: Data were collected by 
performing a retrospective chart review study in the US and 5EU (France, Germany, 
Italy, Spain, UK) with physicians recruited from an online panel. Physicians pro-
vided clinical information on 1 to 4 of their RRDTC patients in an online survey. 
Demographics, disease history, treatment information, and health care resource 
were included and reported descriptively. Health care resource use was compared 
across treatment classes using general linear models. Results: 231 physicians 
participated and provided a total of 700 patient charts (44.1% of charts were from 
the US and 11-12% from each 5EU country). 45.0% of patients were male with a 
mean age at diagnosis of 55.1 years [SD= 12.4]. 52.0% of patients were treated 
with systemic treatment (e.g., 16.9% tyrosine kinase inhibitors [TKIs] only; 13.3% 
chemotherapy only). The remaining 48.0% were either in a watch and wait (“WW”) 
period (20.1%) or were managed with non-systemic palliative therapies (27.9%; eg, 
external beam radiation). Overall, patients averaged 15.87 days hospitalized per 
year (due to disease related complications or side effects). Although not statisti-
